A chest X-ray showing a very prominent wedge-shape area of airspace consolidation in the right lung characteristic of bacterial pneumonia.
|Classification and external resources|
|ICD-10||J12, J13, J14, J15, J16, J17, J18, P23|
Pneumonia (nu-mo'ne-a) is an inflammatory condition of the lung affecting primarily the microscopic air sacs known as alveoli. It is usually caused by infection with viruses or bacteria and less commonly other microorganisms, certain drugs and other conditions such as autoimmune diseases.
Typical signs and symptoms include a cough, chest pain, fever, and difficulty breathing. Diagnostic tools include x-rays and culture of the sputum. Vaccines to prevent certain types of pneumonia are available. Treatment depends on the underlying cause. Pneumonia presumed to be bacterial is treated with antibiotics. If the pneumonia is severe, the affected person is generally hospitalized.
Pneumonia affects approximately 450 million people globally per year, seven percent of population, and results in about 4 million deaths, mostly in developing countries. Although pneumonia was regarded by William Osler in the 19th century as "the captain of the men of death," the advent of antibiotic therapy and vaccines in the 20th century has seen improvements in survival. Nevertheless, in developing countries, and among the very old, the very young, and the chronically ill, pneumonia remains a leading cause of death. In the terminally ill and elderly, especially those with other conditions, pneumonia is often the immediate cause of death. In such cases, particularly when it cuts short the suffering associated with lingering illness, pneumonia has often been called "the old man's friend."
Signs and symptoms
|Shortness of breath|| |
|Chest pain|| |
People with infectious pneumonia often have a productive cough, fever accompanied by shaking chills, shortness of breath, sharp or stabbing chest pain during deep breaths, and an increased rate of breathing. In the elderly, confusion may be the most prominent sign. The typical signs and symptoms in children under five are fever, cough, and fast or difficult breathing.
Fever is not very specific, as it occurs in many other common illnesses, may be absent in those with severe disease, malnutrition or in the elderly. In addition, a cough is frequently absent in children less than 2 months old. More severe signs and symptoms may include blue-tinged skin, decreased thirst, convulsions, persistent vomiting, extremes of temperature, or a decreased level of consciousness.
Bacterial and viral cases of pneumonia usually present with similar symptoms. Some causes are associated with classic, but non-specific, clinical characteristics. Pneumonia caused by Legionella may occur with abdominal pain, diarrhea, or confusion, while pneumonia caused by Streptococcus pneumoniae is associated with rusty colored sputum, and pneumonia caused by Klebsiella may have bloody sputum often described as "currant jelly". Bloody sputum (known as hemoptysis) may also occur with tuberculosis, Gram-negative pneumonia, and lung abscesses as well as more commonly with acute bronchitis. Mycoplasma pneumonia may occur in association with swelling of the lymph nodes in the neck, joint pain, or a middle ear infection. Viral pneumonia presents more commonly with wheezing than does bacterial pneumonia. Pneumonia was historically divided into "typical" and "atypical" based on the belief that the presentation predicted the underlying cause. However, evidence has not supported this distinction, thus it is no longer emphasized.
Pneumonia is due to infections caused primarily by bacteria or viruses and less commonly by fungi and parasites. Although there are more than 100 strains of infectious agents identified, only a few are responsible for the majority of the cases. Mixed infections with both viruses and bacteria may occur in up to 45% of infections in children and 15% of infections in adults. A causative agent may not be isolated in approximately half of cases despite careful testing.
The term pneumonia is sometimes more broadly applied to any condition resulting in inflammation of the lungs (caused for example by autoimmune diseases, chemical burns or drug reactions); however, this inflammation is more accurately referred to as pneumonitis.
Conditions and risk factors that predispose to pneumonia include smoking, immunodeficiency, alcoholism, chronic obstructive pulmonary disease, asthma, chronic kidney disease, and liver disease. The use of acid-suppressing medications—such as proton-pump inhibitors or H2 blockers—is associated with an increased risk of pneumonia. The risk is also increased in old age.
Bacteria are the most common cause of community-acquired pneumonia (CAP), with Streptococcus pneumoniae isolated in nearly 50% of cases. Other commonly isolated bacteria include Haemophilus influenzae in 20%, Chlamydophila pneumoniae in 13%, and Mycoplasma pneumoniae in 3% of cases; Staphylococcus aureus; Moraxella catarrhalis; Legionella pneumophila and Gram-negative bacilli. A number of drug-resistant versions of the above infections are becoming more common, including drug-resistant Streptococcus pneumoniae (DRSP) and methicillin-resistant Staphylococcus aureus (MRSA).
The spreading of organisms is facilitated when risk factors are present. Alcoholism is associated with Streptococcus pneumoniae, anaerobic organisms, and Mycobacterium tuberculosis; smoking facilitates the effects of Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, and Legionella pneumophila. Exposure to birds is associated with Chlamydia psittaci; farm animals with Coxiella burnetti; aspiration of stomach contents with anaerobic organisms; and cystic fibrosis with Pseudomonas aeruginosa and Staphylococcus aureus. Streptococcus pneumoniae is more common in the winter, and should be suspected in persons aspirating a large amount anaerobic organisms.
In adults, viruses account for approximately a third and in children for about 15% of pneumonia cases. Commonly implicated agents include rhinoviruses, coronaviruses, influenza virus, respiratory syncytial virus (RSV), adenovirus, and parainfluenza. Herpes simplex virus rarely causes pneumonia, except in groups such as: newborns, persons with cancer, transplant recipients, and people with significant burns. People following organ transplantation or those otherwise-immunocompromised present high rates of cytomegalovirus pneumonia. Those with viral infections may be secondarily infected with the bacteria Streptococcus pneumoniae, Staphylococcus aureus, or Haemophilus influenzae, particularly when other health problems are present. Different viruses predominate at different periods of the year; during influenza season, for example, influenza may account for over half of all viral cases. Outbreaks of other viruses also occasionally occur, including hantaviruses and coronavirus.
Fungal pneumonia is uncommon, but occurs more commonly in individuals with weakened immune systems due to AIDS, immunosuppressive drugs, or other medical problems. It is most often caused by Histoplasma capsulatum, blastomyces, Cryptococcus neoformans, Pneumocystis jiroveci, and Coccidioides immitis. Histoplasmosis is most common in the Mississippi River basin, and coccidioidomycosis is most common in the Southwestern United States. The number of cases has been increasing in the later half of the 20th century due to increasing travel and rates of immunosuppression in the population.
A variety of parasites can affect the lungs, including Toxoplasma gondii, Strongyloides stercoralis, Ascaris lumbricoides, and Plasmodium malariae. These organisms typically enter the body through direct contact with the skin, ingestion, or via an insect vector. Except for Paragonimus westermani, most parasites do not affect specifically the lungs but involve the lungs secondarily to other sites. Some parasites, in particular those belonging to the Ascaris and Strongyloides genera, stimulate a strong eosinophilic reaction, which may result in eosinophilic pneumonia. In other infections, such as malaria, lung involvement is due primarily to cytokine-induced systemic inflammation. In the developed world these infections are most common in people returning from travel or in immigrants. Around the world, these infections are most common in the immunodeficient.
Idiopathic interstitial pneumonia or noninfectious pneumonia is a class of diffuse lung diseases. They include diffuse alveolar damage, organizing pneumonia, nonspecific interstitial pneumonia, lymphocytic interstitial pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis interstitial lung disease, and usual interstitial pneumonia.
Viruses may reach the lung by a number of different routes. Respiratory syncytial virus is typically contracted when people touch contaminated objects and then they touch their eyes or nose. Other viral infections occur when contaminated airborne droplets are inhaled through the mouth or nose. Once in the upper airway, the viruses may make their way in the lungs, where they invade the cells lining the airways, alveoli, or lung parenchyma. Some viruses such as measles and herpes simplex may reach the lungs via the blood. The invasion of the lungs may lead to varying degrees of cell death. When the immune system responds to the infection, even more lung damage may occur. Primarily white blood cells, mainly mononuclear cells, generate the inflammation. As well as damaging the lungs, many viruses simultaneously affect other organs and thus disrupt other body functions. Viruses also make the body more susceptible to bacterial infections; in this way, bacterial pneumonia can arise as a co-morbid condition.
Most bacteria enter the lungs via small aspirations of organisms residing in the throat or nose. Half of normal people have these small aspirations during sleep. While the throat always contains bacteria, potentially infectious ones reside there only at certain times and under certain conditions. A minority of types of bacteria such as Mycobacterium tuberculosis and Legionella pneumophila reach the lungs via contaminated airborne droplets. Bacteria can spread also via the blood. Once in the lungs, bacteria may invade the spaces between cells and between alveoli, where the macrophages and neutrophils (defensive white blood cells) attempt to inactivate the bacteria. The neutrophils also release cytokines, causing a general activation of the immune system. This leads to the fever, chills, and fatigue common in bacterial pneumonia. The neutrophils, bacteria, and fluid from surrounding blood vessels fill the alveoli, resulting in the consolidation seen on chest X-ray.
Crackles heard in the lungs of a person with pneumonia using a stethoscope.
|Problems playing this file? See media help.|
Pneumonia is typically diagnosed based on a combination of physical signs and a chest X-ray. However, the underlying cause can be difficult to confirm, as there is no definitive test able to distinguish between bacterial and non-bacterial origin. The World Health Organization has defined pneumonia in children clinically based on either a cough or difficulty breathing and a rapid respiratory rate, chest indrawing, or a decreased level of consciousness. A rapid respiratory rate is defined as greater than 60 breaths per minute in children under 2 months old, 50 breaths per minute in children 2 months to 1 year old, or greater than 40 breaths per minute in children 1 to 5 years old. In children, increased respiratory rate and lower chest indrawing are more sensitive than hearing chest crackles with a stethoscope.
In general, in adults, investigations are not needed in mild cases. There is a very low risk of pneumonia if all vital signs and auscultation are normal. In persons requiring hospitalization, pulse oximetry, chest radiography and blood tests—including a complete blood count, serum electrolytes, C-reactive protein level, and possibly liver function tests—are recommended. The diagnosis of influenza-like illness can be made based on the signs and symptoms; however, confirmation of an influenza infection requires testing. Thus, treatment is frequently based on the presence of influenza in the community or a rapid influenza test.
Physical examination may sometimes reveal low blood pressure, high heart rate, or low oxygen saturation. The respiratory rate may be faster than normal, and this may occur a day or two before other signs. Examination of the chest may be normal, but it may show decreased chest expansion on the affected side. Harsh breath sounds from the larger airways that are transmitted through the inflamed lung are termed bronchial breathing and are heard on auscultation with a stethoscope. Crackles (rales) may be heard over the affected area during inspiration. Percussion may be dulled over the affected lung, and increased, rather than decreased, vocal resonance distinguishes pneumonia from a pleural effusion.
A chest radiograph is frequently used in diagnosis. In people with mild disease, imaging is needed only in those with potential complications, those not having improved with treatment, or those in which the cause is uncertain. If a person is sufficiently sick to require hospitalization, a chest radiograph is recommended. Findings do not always match the severity of disease and do not reliably separate between bacterial infection and viral infection.
X-ray presentations of pneumonia may be classified as lobar pneumonia, bronchopneumonia (also known as lobular pneumonia), and interstitial pneumonia. Bacterial, community-acquired pneumonia classically show lung consolidation of one lung segmental lobe, which is known as lobar pneumonia. However, findings may vary, and other patterns are common in other types of pneumonia. Aspiration pneumonia may present with bilateral opacities primarily in the bases of the lungs and on the right side. Radiographs of viral pneumonia may appear normal, appear hyper-inflated, have bilateral patchy areas, or present similar to bacterial pneumonia with lobar consolidation. Radiologic findings may not be present in the early stages of the disease, especially in the presence of dehydration, or may be difficult to be interpreted in the obese or those with a history of lung disease. A CT scan can give additional information in indeterminate cases.
In patients managed in the community, determining the causative agent is not cost-effective and typically does not alter management. For people that do not respond to treatment, sputum culture should be considered, and culture for Mycobacterium tuberculosis should be carried out in persons with a chronic productive cough. Testing for other specific organisms may be recommended during outbreaks, for public health reasons. In those hospitalized for severe disease, both sputum and blood cultures are recommended, as well as testing the urine for antigens to Legionella and Streptococcus. Viral infections can be confirmed via detection of either the virus or its antigens with culture or polymerase chain reaction (PCR), among other techniques. The causative agent is determined in only 15% of cases with routine microbiological tests.
Pneumonitis refers to lung inflammation; pneumonia refers to pneumonitis, usually due to infection but sometimes non-infectious, that has the additional feature of pulmonary consolidation. Pneumonia is most commonly classified by where or how it was acquired: community-acquired, aspiration, healthcare-associated, hospital-acquired, and ventilator-associated pneumonia. It may also be classified by the area of lung affected: lobar pneumonia, bronchial pneumonia and acute interstitial pneumonia; or by the causative organism. Pneumonia in children may additionally be classified based on signs and symptoms as non-severe, severe, or very severe.
Several diseases can present with similar signs and symptoms to pneumonia, such as: chronic obstructive pulmonary disease (COPD), asthma, pulmonary edema, bronchiectasis, lung cancer, and pulmonary emboli. Unlike pneumonia, asthma and COPD typically present with wheezing, pulmonary edema presents with an abnormal electrocardiogram, cancer and bronchiectasis present with a cough of longer duration, and pulmonary emboli presents with acute onset sharp chest pain and shortness of breath.
Prevention includes vaccination, environmental measures and appropriate treatment of other health problems. It is believed that, if appropriate preventive measures were instituted globally, mortality among children could be reduced by 400,000; and, if proper treatment were universally available, childhood deaths could be decreased by another 600,000.
Vaccination prevents against certain bacterial and viral pneumonias both in children and adults. Influenza vaccines are modestly effective against influenza A and B. The Center for Disease Control and Prevention (CDC) recommends yearly vaccination for every person 6 months and older. Immunizing health care workers decreases the risk of viral pneumonia among their patients. When influenza outbreaks occur, medications such as amantadine or rimantadine may help prevent the condition. It is unknown whether zanamivir or oseltamivir is effective due to the fact that the company that manufactures oseltamivir has refused to release the trial data for independent analysis.
Vaccinations against Haemophilus influenzae and Streptococcus pneumoniae have good evidence to support their use. Vaccinating children against Streptococcus pneumoniae has led to a decreased incidence of these infections in adults, because many adults acquire infections from children. A Streptococcus pneumoniae vaccine is available for adults, and has been found to decrease the risk of invasive pneumococcal disease. Other vaccines for which there to support for a protective effect against pneumonia include pertussis, varicella, and measles.
Smoking cessation and reducing indoor air pollution, such as that from cooking indoors with wood or dung, are both recommended. Smoking appears to be the single biggest risk factor for pneumococcal pneumonia in otherwise-healthy adults. Hand hygiene and coughing into one's sleeve may also be effective preventative measures. Wearing surgical masks by the sick may also prevent illness.
Appropriately treating underlying illnesses (such as HIV/AIDS, diabetes mellitus, and malnutrition) can decrease the risk of pneumonia. In children less than 6 months of age, exclusive breast feeding reduces both the risk and severity of disease. In those with HIV/AIDS and a CD4 count of less than 200 cells/uL the antibiotic trimethoprim/sulfamethoxazole decreases the risk of Pneumocystis pneumonia and may also be useful for prevention in those that are immunocomprised but do not have HIV.
Testing pregnant women for Group B Streptococcus and Chlamydia trachomatis, and administering antibiotic treatment, if needed, reduces rates of pneumonia in infants; preventive measures for HIV transmission from mother to child may also be efficient. Suctioning the mouth and throat of infants with meconium-stained amniotic fluid has not been found to reduce the rate of aspiration pneumonia and may cause potential harm, thus this practice is not recommended in the majority of situations. In the frail elderly good oral health care may lower the risk of aspiration pneumonia. Zinc supplementation in children 2 months to five years old appears to reduce rates of pneumonia.
Oral antibiotics, rest, simple analgesics, and fluids usually suffice for complete resolution. However, those with other medical conditions, the elderly, or those with significant trouble breathing may require more advanced care. If the symptoms worsen, the pneumonia does not improve with home treatment, or complications occur, hospitalization may be required. Worldwide, approximately 7–13% of cases in children result in hospitalization, whereas in the developed world between 22 and 42% of adults with community-acquired pneumonia are admitted. The CURB-65 score is useful for determining the need for admission in adults. If the score is 0 or 1, people can typically be managed at home; if it is 2, a short hospital stay or close follow-up is needed; if it is 3–5, hospitalization is recommended. In children those with respiratory distress or oxygen saturations of less than 90% should be hospitalized. The utility of chest physiotherapy in pneumonia has not yet been determined. Non-invasive ventilation may be beneficial in those admitted to the intensive care unit. Over-the-counter cough medicine has not been found to be effective nor has the use of zinc in children. There is insufficient evidence for mucolytics.
Antibiotics improve outcomes in those with bacterial pneumonia. Antibiotic choice depends initially on the characteristics of the person affected, such as age, underlying health, and the location the infection was acquired. In the UK, empiric treatment with amoxicillin is recommended as the first line for community-acquired pneumonia, with doxycycline or clarithromycin as alternatives. In North America, where the "atypical" forms of community-acquired pneumonia are more common, macrolides (such as azithromycin or erythromycin), and doxycycline have displaced amoxicillin as first-line outpatient treatment in adults. In children with mild or moderate symptoms, amoxicillin remains the first line. The use of fluoroquinolones in uncomplicated cases is discouraged due to concerns about side-effects and generating resistance in light of there being no greater clinical benefit. The duration of treatment has traditionally been seven to ten days, but increasing evidence suggests that shorter courses (three to five days) are similarly effective. Recommended for hospital-acquired pneumonia include third- and fourth-generation cephalosporins, carbapenems, fluoroquinolones, aminoglycosides, and vancomycin. These antibiotics are often given intravenously and used in combination. In those treated in hospital, more than 90% improve with the initial antibiotics.
Neuraminidase inhibitors may be used to treat viral pneumonia caused by influenza viruses (influenza A and influenza B). No specific antiviral medications are recommended for other types of community acquired viral pneumonias including SARS coronavirus, adenovirus, hantavirus, and parainfluenza virus. Influenza A may be treated with rimantadine or amantadine, while influenza A or B may be treated with oseltamivir, zanamivir or peramivir. These are of most benefit if they are started within 48 hours of the onset of symptoms. Many strains of H5N1 influenza A, also known as avian influenza or "bird flu," have shown resistance to rimantadine and amantadine. The use of antibiotics in viral pneumonia is recommended by some experts, as it is impossible to rule out a complicating bacterial infection. The British Thoracic Society recommends that antibiotics be withheld in those with mild disease. The use of corticosteroids is controversial.
In general, aspiration pneumonitis is treated conservatively with antibiotics indicated only for aspiration pneumonia. The choice of antibiotic will depend on several factors, including the suspected causative organism and whether pneumonia was acquired in the community or developed in a hospital setting. Common options include clindamycin, a combination of a beta-lactam antibiotic and metronidazole, or an aminoglycoside. Corticosteroids are sometimes used in aspiration pneumonia, but there is limited evidence to support their effectiveness.
With treatment, most types of bacterial pneumonia will stabilize in 3–6 days. It often takes a few weeks before most symptoms resolve. X-ray finding typically clear within four weeks and mortality is low (less than 1%). In the elderly or people with other lung problems, recovery may take more than 12 weeks. In persons requiring hospitalization, mortality may be as high as 10%, and in those requiring intensive care it may reach 30–50%. Pneumonia is the most common hospital-acquired infection that causes death. Before the advent of antibiotics, mortality was typically 30% in those that were hospitalized.
Complications may occur in particular in the elderly and those with underlying health problems. This may include, among others: empyema, lung abscess, bronchiolitis obliterans, acute respiratory distress syndrome, sepsis, and worsening of underlying health problems.
Clinical prediction rules
- Pneumonia severity index (or PSI Score)
- CURB-65 score, which takes into account the severity of symptoms, any underlying diseases, and age
Pleural effusion, empyema, and abscess
In pneumonia, a collection of fluid may form in the space that surrounds the lung. Occasionally, microorganisms will infect this fluid, causing an empyema. To distinguish an empyema from the more common simple parapneumonic effusion, the fluid may be collected with a needle (thoracentesis), and examined. If this shows evidence of empyema, complete drainage of the fluid is necessary, often requiring a drainage catheter. In severe cases of empyema, surgery may be needed. If the infected fluid is not drained, the infection may persist, because antibiotics do not penetrate well into the pleural cavity. If the fluid is sterile, it must be drained only if it is causing symptoms or remains unresolved.
In rare circumstances, bacteria in the lung will form a pocket of infected fluid called a lung abscess. Lung abscesses can usually be seen with a chest X-ray but frequently require a chest CT scan to confirm the diagnosis. Abscesses typically occur in aspiration pneumonia, and often contain several types of bacteria. Long-term antibiotics are usually adequate to treat a lung abscess, but sometimes the abscess must be drained by a surgeon or radiologist.
Respiratory and circulatory failure
Pneumonia can cause respiratory failure by triggering acute respiratory distress syndrome (ARDS), which results from a combination of infection and inflammatory response. The lungs quickly fill with fluid and become stiff. This stiffness, combined with severe difficulties extracting oxygen due to the alveolar fluid, may require long periods of mechanical ventilation for survival.
Sepsis is a potential complication of pneumonia but occurs usually in people with poor immunity or hyposplenism. The organisms most commonly involved are Streptococcus pneumoniae, Haemophilus influenzae, and Klebsiella pneumoniae. Other causes of the symptoms should be considered such as a myocardial infarction or a pulmonary embolism.
Pneumonia is a common illness affecting approximately 450 million people a year and occurring in all parts of the world. It is a major cause of death among all age groups resulting in 4 million deaths (7% of the world's total death) yearly. Rates are greatest in children less than five, and adults older than 75 years. It occurs about five times more frequently in the developing world than in the developed world. Viral pneumonia accounts for about 200 million cases. In the United States, as of 2009, pneumonia is the 8th leading cause of death.
In 2008, pneumonia occurred in approximately 156 million children (151 million in the developing world and 5 million in the developed world). In 2010, it resulted in 1.3 million deaths, or 18% of all deaths in those under five years, of which 95% occurred in the developing world. Countries with the greatest burden of disease include India (43 million), China (21 million) and Pakistan (10 million). It is the leading cause of death among children in low income countries. Many of these deaths occur in the newborn period. The World Health Organization estimates that one in three newborn infant deaths is due to pneumonia. Approximately half of these deaths can be prevented, as they are caused by the bacteria for which an effective vaccine is available. In 2011, pneumonia was the most common reason for admission to the hospital after an emergency department visit in the U.S. for infants and children.
Pneumonia has been a common disease throughout human history. The symptoms were described by Hippocrates (c. 460 BC – 370 BC): "Peripneumonia, and pleuritic affections, are to be thus observed: If the fever be acute, and if there be pains on either side, or in both, and if expiration be if cough be present, and the sputa expectorated be of a blond or livid color, or likewise thin, frothy, and florid, or having any other character different from the common... When pneumonia is at its height, the case is beyond remedy if he is not purged, and it is bad if he has dyspnoea, and urine that is thin and acrid, and if sweats come out about the neck and head, for such sweats are bad, as proceeding from the suffocation, rales, and the violence of the disease which is obtaining the upper hand." However, Hippocrates referred to pneumonia as a disease "named by the ancients." He also reported the results of surgical drainage of empyemas. Maimonides (1135–1204 AD) observed: "The basic symptoms that occur in pneumonia and that are never lacking are as follows: acute fever, sticking pleuritic pain in the side, short rapid breaths, serrated pulse and cough." This clinical description is quite similar to those found in modern textbooks, and it reflected the extent of medical knowledge through the Middle Ages into the 19th century.
Edwin Klebs was the first to observe bacteria in the airways of persons having died of pneumonia in 1875. Initial work identifying the two common bacterial causes, Streptococcus pneumoniae and Klebsiella pneumoniae, was performed by Carl Friedländer and Albert Fränkel in 1882 and 1884, respectively. Friedländer's initial work introduced the Gram stain, a fundamental laboratory test still used today to identify and categorize bacteria. Christian Gram's paper describing the procedure in 1884 helped to differentiate the two bacteria, and showed that pneumonia could be caused by more than one microorganism.
Sir William Osler, known as "the father of modern medicine," appreciated the death and disability caused by pneumonia, describing it as the "captain of the men of death" in 1918, as it had overtaken tuberculosis as one of the leading causes of death in this time. This phrase was originally coined by John Bunyan in reference to "consumption" (tuberculosis). Osler also described pneumonia as "the old man's friend" as death was often quick and painless when there were many slower more painful ways to die.
Several developments in the 1900s improved the outcome for those with pneumonia. With the advent of penicillin and other antibiotics, modern surgical techniques, and intensive care in the 20th century, mortality from pneumonia, had approached 30%, dropped precipitously in the developed world. Vaccination of infants against Haemophilus influenzae type B began in 1988 and led to a dramatic decline in cases shortly thereafter. Vaccination against Streptococcus pneumoniae in adults began in 1977, and in children in 2000, resulting in a similar decline.
Society and culture
Due to the high burden of disease in developing countries and a relatively low awareness of the disease in developed countries, the global health community has declared 12 November as World Pneumonia Day, a day for concerned citizens and policy makers to take action against the disease.
The global economic cost of community-acquired pneumonia has been estimated at $17 billion annually. Other estimates are considerably higher. In 2012 the estimated aggregate costs of treating pneumonia in the United States were $20 billion; the median cost of a single pneumonia-related hospitalization is over $15,000. According to data released by the Centers for Medicare and Medicaid Services, average 2012 hospital charges for inpatient treatment of uncomplicated pneumonia in the U.S. were $24,549 and ranged as high as $124,000. The average cost of an emergency room consult for pneumonia was $943 and the average cost for medication was $66. Aggregate annual costs of treating pneumonia in Europe have been estimated at €10 billion.
- ↑ 1.0 1.1 McLuckie, A., ed. (2009). Respiratory disease and its management. New York: Springer. p. 51. ISBN 978-1-84882-094-4.
- ↑ Leach, Richard E. (2009). Acute and Critical Care Medicine at a Glance (2nd ed.). Wiley-Blackwell. ISBN 1-4051-6139-6. Retrieved 2011-04-21.
- ↑ Jeffrey C. Pommerville (2010). Alcamo's Fundamentals of Microbiology (9th ed.). Sudbury MA: Jones & Bartlett. p. 323. ISBN 0-7637-6258-X.
- ↑ Ashby, Bonnie; Turkington, Carol (2007). The encyclopedia of infectious diseases (3rd ed.). New York: Facts on File. p. 242. ISBN 0-8160-6397-4. Retrieved 2011-04-21.
- ↑ Osler, William (1901). Principles and Practice of Medicine, 4th Edition. New York: D. Appleton and Company. p. 108.
- ↑ 6.0 6.1 6.2 6.3 6.4 6.5 6.6 6.7 6.8 6.9 6.10 6.11 6.12 6.13 6.14 6.15 6.16 6.17 6.18 6.19 6.20 6.21 6.22 6.23 Ruuskanen, O; Lahti, E; Jennings, LC; Murdoch, DR (2011-04-09). "Viral pneumonia". Lancet 377 (9773): 1264–75. doi:10.1016/S0140-6736(10)61459-6. PMID 21435708.
- ↑ George, Ronald B. (2005). Chest medicine : essentials of pulmonary and critical care medicine (5th ed.). Philadelphia, PA: Lippincott Williams & Wilkins. p. 353. ISBN 9780781752732.
- ↑ 8.0 8.1 8.2 8.3 8.4 8.5 8.6 8.7 8.8 8.9 Eddy, Orin (Dec 2005). "Community-Acquired Pneumonia: From Common Pathogens To Emerging Resistance". Emergency Medicine Practice 7 (12).
- ↑ 9.0 9.1 Tintinalli, Judith E. (2010). Emergency Medicine: A Comprehensive Study Guide (Emergency Medicine (Tintinalli)). New York: McGraw-Hill Companies. p. 480. ISBN 0-07-148480-9.
- ↑ 10.0 10.1 10.2 10.3 10.4 10.5 Hoare Z; Lim WS (2006). "Pneumonia: update on diagnosis and management" (PDF). BMJ 332 (7549): 1077–9. doi:10.1136/bmj.332.7549.1077. PMC 1458569. PMID 16675815.
- ↑ 11.0 11.1 11.2 11.3 11.4 11.5 11.6 11.7 11.8 11.9 11.10 11.11 Singh, V; Aneja, S (March 2011). "Pneumonia — management in the developing world". Paediatric respiratory reviews 12 (1): 52–9. doi:10.1016/j.prrv.2010.09.011. PMID 21172676.
- ↑ 12.0 12.1 12.2 12.3 12.4 12.5 12.6 12.7 12.8 12.9 12.10 12.11 12.12 12.13 12.14 12.15 12.16 12.17 12.18 12.19 Nair, GB; Niederman, MS (November 2011). "Community-acquired pneumonia: an unfinished battle". The Medical clinics of North America 95 (6): 1143–61. doi:10.1016/j.mcna.2011.08.007. PMID 22032432.
- ↑ 13.0 13.1 13.2 13.3 13.4 13.5 13.6 "Pneumonia (Fact sheet N°331)". World Health Organization. August 2012.
- ↑ Darby, J; Buising, K (October 2008). "Could it be Legionella?". Australian family physician 37 (10): 812–5. PMID 19002299.
- ↑ Ortqvist, A; Hedlund, J; Kalin, M (December 2005). "Streptococcus pneumoniae: epidemiology, risk factors, and clinical features". Seminars in respiratory and critical care medicine 26 (6): 563–74. doi:10.1055/s-2005-925523. PMID 16388428.
- ↑ 16.0 16.1 16.2 16.3 16.4 16.5 16.6 16.7 16.8 16.9 Murray and Nadel (2010). Chapter 32.
- ↑ Lowe, J. F.; Stevens, Alan (2000). Pathology (2nd ed.). St. Louis: Mosby. p. 197. ISBN 0-7234-3200-7.
- ↑ Snydman, editors, Raleigh A. Bowden, Per Ljungman, David R. (2010). Transplant infections (3rd ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 187. ISBN 978-1-58255-820-2.
- ↑ Eom, CS; Jeon, CY; Lim, JW; Cho, EG; Park, SM; Lee, KS (22 February 2011). "Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis". CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne 183 (3): 310–9. doi:10.1503/cmaj.092129. PMC 3042441. PMID 21173070.
- ↑ 20.0 20.1 20.2 20.3 20.4 20.5 20.6 20.7 20.8 Sharma, S; Maycher, B; Eschun, G (May 2007). "Radiological imaging in pneumonia: recent innovations". Current Opinion in Pulmonary Medicine 13 (3): 159–69. doi:10.1097/MCP.0b013e3280f3bff4. PMID 17414122.
- ↑ 21.0 21.1 21.2 Anevlavis S; Bouros D (February 2010). "Community acquired bacterial pneumonia". Expert Opin Pharmacother 11 (3): 361–74. doi:10.1517/14656560903508770. PMID 20085502.
- ↑ 22.0 22.1 22.2 22.3 22.4 22.5 22.6 22.7 22.8 22.9 Murray and Nadel (2010). Chapter 31.
- ↑ 23.0 23.1 Figueiredo LT (September 2009). "Viral pneumonia: epidemiological, clinical, pathophysiological, and therapeutic aspects". J Bras Pneumol 35 (9): 899–906. doi:10.1590/S1806-37132009000900012. PMID 19820817.
- ↑ 24.0 24.1 Behera, D. (2010). Textbook of pulmonary medicine (2nd ed.). New Delhi: Jaypee Brothers Medical Pub. pp. 391–394. ISBN 8184487495.
- ↑ 25.0 25.1 Maskell, Nick; Millar, Ann (2009). Oxford desk reference. Oxford: Oxford University Press. p. 196. ISBN 9780199239122.
- ↑ 26.0 26.1 26.2 26.3 26.4 26.5 Murray and Nadel (2010). Chapter 37.
- ↑ Vijayan, VK (May 2009). "Parasitic lung infections". Current Opinion in Pulmonary Medicine 15 (3): 274–82. doi:10.1097/MCP.0b013e328326f3f8. PMID 19276810.
- ↑ ed. in chief Richard K. Root. Eds. Francis Waldvogel (1999). Clinical infectious diseases : a practical approach. New York, NY [u.a.]: Oxford Univ. Press. p. 833. ISBN 978-0-19-508103-9.
- ↑ Volume editors, Ulrich Costabel (2007). Diffuse parenchymal lung disease : ... 47 tables ([Online-Ausg.] ed.). Basel: Karger. p. 4. ISBN 978-3-8055-8153-0.
- ↑ 30.0 30.1 Ranganathan, SC; Sonnappa, S (February 2009). "Pneumonia and other respiratory infections". Pediatric clinics of North America 56 (1): 135–56, xi. doi:10.1016/j.pcl.2008.10.005. PMID 19135585.
- ↑ 31.0 31.1 editors, Gary R. Fleisher, Stephen Ludwig ; associate editors, Richard G. Bachur [et at.] (2010). Textbook of pediatric emergency medicine (6th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins Health. p. 914. ISBN 1605471593.
- ↑ Hammer, edited by Stephen J. McPhee, Gary D. (2010). Pathophysiology of disease : an introduction to clinical medicine (6th ed.). New York: McGraw-Hill Medical. pp. Chapter 4. ISBN 0071621679.
- ↑ 33.0 33.1 Fein, Alan (2006). Diagnosis and management of pneumonia and other respiratory infections (2nd ed.). Caddo, OK: Professional Communications. pp. 28–29. ISBN 1884735630.
- ↑ Kumar, Vinay (2010). Robbins and Cotran pathologic basis of disease. (8th ed.). Philadelphia, PA: Saunders/Elsevier. pp. Chapter 15. ISBN 1416031219.
- ↑ 35.0 35.1 Lynch, T; Bialy, L; Kellner, JD; Osmond, MH; Klassen, TP; Durec, T; Leicht, R; Johnson, DW (2010-08-06). Huicho, Luis, ed. "A systematic review on the diagnosis of pediatric bacterial pneumonia: when gold is bronze". PLoS ONE 5 (8): e11989. doi:10.1371/journal.pone.0011989. PMC 2917358. PMID 20700510.
- ↑ 36.0 36.1 Ezzati, edited by Majid; Lopez, Alan D.; Rodgers, Anthony; Murray, Christopher J.L. (2004). Comparative quantification of health risks. Genève: Organisation mondiale de la santé. p. 70. ISBN 978-92-4-158031-1.
- ↑ 37.0 37.1 37.2 37.3 37.4 37.5 37.6 37.7 37.8 37.9 37.10 37.11 37.12 37.13 Lim, WS; Baudouin, SV; George, RC; Hill, AT; Jamieson, C; Le Jeune, I; Macfarlane, JT; Read, RC; Roberts, HJ; Levy, ML; Wani, M; Woodhead, MA; Pneumonia Guidelines Committee of the BTS Standards of Care, Committee (October 2009). "BTS guidelines for the management of community acquired pneumonia in adults: update 2009". Thorax 64 (Suppl 3): iii1–55. doi:10.1136/thx.2009.121434. PMID 19783532.
- ↑ Saldías, F; Méndez, JI; Ramírez, D; Díaz, O (April 2007). "[Predictive value of history and physical examination for the diagnosis of community-acquired pneumonia in adults: a literature review]". Revista medica de Chile 135 (4): 517–28. PMID 17554463.
- ↑ 39.0 39.1 Call, SA; Vollenweider, MA; Hornung, CA; Simel, DL; McKinney, WP (2005-02-23). "Does this patient have influenza?". JAMA: the Journal of the American Medical Association 293 (8): 987–97. doi:10.1001/jama.293.8.987. PMID 15728170.
- ↑ Helms, editors, William E. Brant, Clyde A. (2012-03-20). Fundamentals of diagnostic radiology (4th ed.). Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins. p. 435. ISBN 9781608319114.
- ↑ 41.0 41.1 41.2 41.3 Mandell, LA; Wunderink, RG; Anzueto, A; Bartlett, JG; Campbell, GD; Dean, NC; Dowell, SF; File TM, Jr; Musher, DM; Niederman, MS; Torres, A; Whitney, CG; Infectious Diseases Society of America; American Thoracic Society (1 March 2007). "Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 44 (Suppl 2): S27–72. doi:10.1086/511159. PMID 17278083.
- ↑ Stedman's medical dictionary. (28th ed.). Philadelphia: Lippincott Williams & Wilkins. 2006. ISBN 978-0-7817-6450-6.
- ↑ Dunn, L (June 29 – July 5, 2005). "Pneumonia: classification, diagnosis and nursing management". Nursing standard (Royal College of Nursing (Great Britain) : 1987) 19 (42): 50–4. doi:10.7748/ns2005.06.19.42.50.c3901. PMID 16013205.
- ↑ organization, World health (2005). Pocket book of hospital care for children : guidelines for the management of common illnesses with limited resources. Geneva: World Health Organization. p. 72. ISBN 978-92-4-154670-6.
- ↑ Jefferson, T; Di Pietrantonj, C; Rivetti, A; Bawazeer, GA; Al-Ansary, LA; Ferroni, E (2010-07-07). Jefferson, Tom, ed. "Vaccines for preventing influenza in healthy adults". Cochrane Database of Systematic Reviews (7): CD001269. doi:10.1002/14651858.CD001269.pub4. PMID 20614424.
- ↑ "Seasonal Influenza (Flu)". Center for Disease Control and Prevention. Retrieved 29 June 2011.
- ↑ Jefferson T; Deeks, JJ; Demicheli, V; Rivetti, D; Rudin, M (2004). Jefferson, Tom, ed. "Amantadine and rimantadine for preventing and treating influenza A in adults". Cochrane Database Syst Rev (3): CD001169. doi:10.1002/14651858.CD001169.pub2. PMID 15266442.
- ↑ Jefferson, T; Jones, MA; Doshi, P; Del Mar, CB; Heneghan, CJ; Hama, R; Thompson, MJ (18 January 2012). Jefferson, Tom, ed. "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children". Cochrane Database of Systematic Reviews 1: CD008965. doi:10.1002/14651858.CD008965.pub3. PMID 22258996.
- ↑ Moberley, SA; Holden, J; Tatham, DP; Andrews, RM (2008-01-23). Andrews, Ross M, ed. "Vaccines for preventing pneumococcal infection in adults". Cochrane Database of Systematic Reviews (1): CD000422. doi:10.1002/14651858.CD000422.pub2. PMID 18253977.
- ↑ 50.0 50.1 50.2 "Pneumonia Can Be Prevented — Vaccines Can Help". Centers for Disease Control and Prevention. Retrieved 22 October 2012.
- ↑ Gray, DM; Zar, HJ (May 2010). "Community-acquired pneumonia in HIV-infected children: a global perspective". Current Opinion in Pulmonary Medicine 16 (3): 208–16. doi:10.1097/MCP.0b013e3283387984. PMID 20375782.
- ↑ Huang, L; Cattamanchi, A; Davis, JL; den Boon, S; Kovacs, J; Meshnick, S; Miller, RF; Walzer, PD; Worodria, W; Masur, H; International HIV-associated Opportunistic Pneumonias (IHOP), Study; Lung HIV, Study (June 2011). "HIV-associated Pneumocystis pneumonia". Proceedings of the American Thoracic Society 8 (3): 294–300. doi:10.1513/pats.201009-062WR. PMC 3132788. PMID 21653531.
- ↑ Green H, Paul M, Vidal L, Leibovici L (2007). Green, Hefziba, ed. "Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients". Cochrane Database Syst Rev (3): CD005590. doi:10.1002/14651858.CD005590.pub2. PMID 17636808.
- ↑ Taminato, M; Fram, D; Torloni, MR; Belasco, AG; Saconato, H; Barbosa, DA (November–December 2011). "Screening for group B Streptococcus in pregnant women: a systematic review and meta-analysis". Revista latino-americana de enfermagem 19 (6): 1470–8. doi:10.1590/s0104-11692011000600026. PMID 22249684.
- ↑ Darville, T (October 2005). "Chlamydia trachomatis infections in neonates and young children". Seminars in pediatric infectious diseases 16 (4): 235–44. doi:10.1053/j.spid.2005.06.004. PMID 16210104.
- ↑ Global Action Plan for Prevention and Control of Pneumonia (GAPP) (PDF). World Health Organization. 2009.
- ↑ 57.0 57.1 Roggensack, A; Jefferies, AL; Farine, D; Basso, M; Delisle, MF; Hudon, L; Mundle, WR; Murphy-Kaulbeck, LC; Ouellet, A; Pressey, T (April 2009). "Management of meconium at birth". Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC 31 (4): 353–4, 355–7. PMID 19497156.
- ↑ van der Maarel-Wierink, CD; Vanobbergen, JN; Bronkhorst, EM; Schols, JM; de Baat, C (6 March 2012). "Oral health care and aspiration pneumonia in frail older people: a systematic literature review". Gerodontology 30 (1): 3–9. doi:10.1111/j.1741-2358.2012.00637.x. PMID 22390255.
- ↑ Lassi, ZS.; Haider, BA.; Bhutta, ZA. (2010). "Zinc supplementation for the prevention of pneumonia in children aged 2 months to 59 months.". Cochrane Database Syst Rev (12): CD005978. doi:10.1002/14651858.CD005978.pub2. PMID 21154362.
- ↑ 60.0 60.1 Bradley, JS; Byington, CL; Shah, SS; Alverson, B; Carter, ER; Harrison, C; Kaplan, SL; Mace, SE; McCracken GH, Jr; Moore, MR; St Peter, SD; Stockwell, JA; Swanson, JT (2011-08-31). "The Management of Community-Acquired Pneumonia in Infants and Children Older Than 3 Months of Age: Clinical Practice Guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America". Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 53 (7): e25–76. doi:10.1093/cid/cir531. PMID 21880587.
- ↑ Yang, M; Yuping, Y; Yin, X; Wang, BY; Wu, T; Liu, GJ; Dong, BR (2010-02-17). Dong, Bi Rong, ed. "Chest physiotherapy for pneumonia in adults". Cochrane Database of Systematic Reviews (2): CD006338. doi:10.1002/14651858.CD006338.pub2. PMID 20166082.
- ↑ Zhang, Y; Fang, C; Dong, BR; Wu, T; Deng, JL (14 March 2012). Dong, Bi Rong, ed. "Oxygen therapy for pneumonia in adults". Cochrane Database of Systematic Reviews 3: CD006607. doi:10.1002/14651858.CD006607.pub4. PMID 22419316.
- ↑ 63.0 63.1 Chang CC, Cheng AC, Chang AB (2012). Chang, Christina C, ed. "Over-the-counter (OTC) medications to reduce cough as an adjunct to antibiotics for acute pneumonia in children and adults". Cochrane Database Syst Rev 2: CD006088. doi:10.1002/14651858.CD006088.pub3. PMID 22336815.
- ↑ Haider, BA; Lassi, ZS; Ahmed, A; Bhutta, ZA (5 October 2011). Bhutta, Zulfiqar A, ed. "Zinc supplementation as an adjunct to antibiotics in the treatment of pneumonia in children 2 to 59 months of age". Cochrane Database of Systematic Reviews (10): CD007368. doi:10.1002/14651858.CD007368.pub2. PMID 21975768.
- ↑ 65.0 65.1 65.2 Kabra SK; Lodha, R; Pandey, RM (2010). Kabra, Sushil K, ed. "Antibiotics for community-acquired pneumonia in children". Cochrane Database Syst Rev 3 (3): CD004874. doi:10.1002/14651858.CD004874.pub3. PMID 20238334.
- ↑ Lutfiyya MN; Henley, E; Chang, LF; Reyburn, SW (February 2006). "Diagnosis and treatment of community-acquired pneumonia" (PDF). Am Fam Physician 73 (3): 442–50. PMID 16477891.
- ↑ Eliakim-Raz, N; Robenshtok, E; Shefet, D; Gafter-Gvili, A; Vidal, L; Paul, M; Leibovici, L (12 September 2012). Eliakim-Raz, Noa, ed. "Empiric antibiotic coverage of atypical pathogens for community-acquired pneumonia in hospitalized adults". Cochrane Database of Systematic Reviews 9: CD004418. doi:10.1002/14651858.CD004418.pub4. PMID 22972070.
- ↑ Scalera NM; File, TM (April 2007). "How long should we treat community-acquired pneumonia?". Current Opinion in Infectious Diseases 20 (2): 177–81. doi:10.1097/QCO.0b013e3280555072. PMID 17496577.
- ↑ 69.0 69.1 American Thoracic Society; Infectious Diseases Society of America (February 2005). "Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia". Am J Respir Crit Care Med 171 (4): 388–416. doi:10.1164/rccm.200405-644ST. PMID 15699079.
- ↑ 70.0 70.1 Marik, PE (May 2011). "Pulmonary aspiration syndromes". Current Opinion in Pulmonary Medicine 17 (3): 148–54. doi:10.1097/MCP.0b013e32834397d6. PMID 21311332.
- ↑ O'Connor S (2003). "Aspiration pneumonia and pneumonitis". Australian Prescriber 26 (1): 14–7.
- ↑ 72.0 72.1 Behera, D. (2010). Textbook of pulmonary medicine (2nd ed.). New Delhi: Jaypee Brothers Medical Pub. pp. 296–297. ISBN 9788184487497.
- ↑ 73.0 73.1 73.2 Cunha (2010). Pages6-18.
- ↑ Rello, J (2008). "Demographics, guidelines, and clinical experience in severe community-acquired pneumonia". Critical care (London, England). 12 Suppl 6 (Suppl 6): S2. doi:10.1186/cc7025. PMC 2607112. PMID 19105795.
- ↑ 75.0 75.1 75.2 75.3 75.4 75.5 75.6 75.7 75.8 Yu, H (March 2011). "Management of pleural effusion, empyema, and lung abscess". Seminars in interventional radiology 28 (1): 75–86. doi:10.1055/s-0031-1273942. PMC 3140254. PMID 22379278.
- ↑ Cunha (2010). Pages 250–251.
- ↑ "WHO Disease and injury country estimates". World Health Organization (WHO). 2004. Retrieved 11 November 2009.
- ↑ Liu, L; Johnson, HL; Cousens, S; Perin, J; Scott, S; Lawn, JE; Rudan, I; Campbell, H; Cibulskis, R; Li, M; Mathers, C; Black, RE; Child Health Epidemiology Reference Group of WHO and, UNICEF (Jun 9, 2012). "Global, regional, and national causes of child mortality: an updated systematic analysis for 2010 with time trends since 2000". Lancet 379 (9832): 2151–61. doi:10.1016/S0140-6736(12)60560-1. PMID 22579125.
- ↑ Rudan, I; Boschi-Pinto, C; Biloglav, Z; Mulholland, K; Campbell, H (May 2008). "Epidemiology and etiology of childhood pneumonia". Bulletin of the World Health Organization 86 (5): 408–16. doi:10.2471/BLT.07.048769. PMC 2647437. PMID 18545744.
- ↑ Garenne M; Ronsmans, C; Campbell, H (1992). "The magnitude of mortality from acute respiratory infections in children under 5 years in developing countries". World Health Stat Q 45 (2–3): 180–91. PMID 1462653.
- ↑ WHO (1999). "Pneumococcal vaccines. WHO position paper". Wkly. Epidemiol. Rec. 74 (23): 177–83. PMID 10437429.
- ↑ Weiss AJ, Wier LM, Stocks C, Blanchard J (June 2014). "Overview of Emergency Department Visits in the United States, 2011". HCUP Statistical Brief #174. Rockville, MD: Agency for Healthcare Research and Quality.
- ↑ 83.0 83.1 Feigin, Ralph (2004). Textbook of Pediatric Infectious Diseases (5th ed.). Philadelphia: W. B. Saunders. p. 299. ISBN 978-0-7216-9329-3.
- ↑ Hippocrates On Acute Diseases wikisource link
- ↑ Maimonides, Fusul Musa ("Pirkei Moshe").
- ↑ Klebs E (1875-12-10). "Beiträge zur Kenntniss der pathogenen Schistomyceten. VII Die Monadinen" [Signs for Recognition of the Pathogen Schistomyceten]. Arch. Exptl. Pathol. Parmakol. 4 (5/6): 40–488.
- ↑ Friedländer C (1882-02-04). "Über die Schizomyceten bei der acuten fibrösen Pneumonie". Virchow's Arch pathol. Anat. U. Physiol. 87 (2): 319–324. doi:10.1007/BF01880516.
- ↑ Fraenkel A (1884-04-21). "Über die genuine Pneumonie, Verhandlungen des Congress für innere Medicin". Dritter Congress 3: 17–31.
- ↑ Gram C (1884-03-15). "Über die isolierte Färbung der Schizomyceten in Schnitt- und Trocken-präparaten". Fortschr. Med 2 (6): 185–9.
- ↑ edited by J.F. Tomashefski, Jr.  et al. (2008). Dail and Hammar's pulmonary pathology (3rd ed.). New York: Springer. p. 228. ISBN 978-0-387-98395-0.
- ↑ William Osler, Thomas McCrae (1920). The principles and practice of medicine: designed for the use of practitioners and students of medicine (9th ed.). D. Appleton. p. 78.
- ↑ Adams WG; Deaver, KA; Cochi, SL; et al. (January 1993). "Decline of childhood Haemophilus influenzae type B (Hib) disease in the Hib vaccine era". JAMA 269 (2): 221–6. doi:10.1001/jama.1993.03500020055031. PMID 8417239.
- ↑ Whitney CG; Farley, MM; Hadler, J; et al. (May 2003). "Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine". N. Engl. J. Med. 348 (18): 1737–46. doi:10.1056/NEJMoa022823. PMID 12724479.
- ↑ "World Pneumonia Day Official Website". World Pneumonia Day Official Website. Fiinex. Retrieved 13 August 2011.
- ↑ "Household Component Summary Data Tables".
- ↑ "Household Component Summary Data Tables".
- ↑ "One hospital charges $8,000 — another, $38,000 - The Washington Post".
- ↑ Welte T, Torres A, Nathwani D (January 2012). "Clinical and economic burden of community-acquired pneumonia among adults in Europe". Thorax 67 (1): 71–9. doi:10.1136/thx.2009.129502. PMID 20729232.